Last reviewed · How we verify
BCX4208
BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses.
BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses. Used for Autoimmune conditions (Phase 2 development), Inflammatory disorders.
At a glance
| Generic name | BCX4208 |
|---|---|
| Sponsor | BioCryst Pharmaceuticals |
| Drug class | PNP inhibitor |
| Target | PNP (purine nucleoside phosphorylase) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PNP, BCX4208 causes accumulation of deoxyadenosine, which is preferentially toxic to T cells with high deoxyadenosine kinase activity, particularly autoreactive T cells. This selective depletion of pathogenic T cells while sparing regulatory T cells creates an immunomodulatory effect intended to treat autoimmune and inflammatory conditions. The mechanism allows for targeted immune suppression without broad immunosuppression.
Approved indications
- Autoimmune conditions (Phase 2 development)
- Inflammatory disorders
Common side effects
- Hyperuricemia
- Gout
- Lymphopenia
Key clinical trials
- A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency (PHASE2)
- Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol (PHASE2)
- Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout (PHASE2)
- Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCX4208 CI brief — competitive landscape report
- BCX4208 updates RSS · CI watch RSS
- BioCryst Pharmaceuticals portfolio CI